The study looks at a new individualized therapy, V940, combined with pembrolizumab (a type of cancer treatment) for people with advanced skin cancer called cutaneous squamous cell carcinoma (cSCC). This cancer affects the skin cells and can be treated with surgery. The study is in two phases: Phase 2 tests different treatment combinations to see how safe and effective they are. Phase 3 will expand the study with more participants if Phase 2 results are good. The study hopes to improve how long patients live without cancer coming back.

• Participants will receive either the new treatment with surgery or surgery alone.
• The study may involve several visits for treatments and checkups.
• Participants must have a specific type of skin cancer to join.

Eligibility includes having a resectable (surgically removable) cSCC and not having other skin cancers or distant spread of the disease. Participants must not have received certain treatments before and must meet health criteria, such as having good organ function and not having severe allergies to study drugs. Women must not be pregnant and should use effective birth control. The study excludes people with other active cancers, serious infections, or recent heart attacks.